![Page 1: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/1.jpg)
www.gu.s
e
Preclinical dementia –
Implications for prevention
Ingmar Skoog
Föreståndare för AGECAP Centrum i Göteborg
Neuropsykiatrisk Epidemiologi
Institutionen för Klinisk Neurovetenskap och Fysiologi
Sahlgrenska Akademin
Göteborgs Universitet
![Page 2: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/2.jpg)
Sahlgrenska akademin
Neuropsychiatric Epidemiology
EPINEP
![Page 3: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/3.jpg)
www.gu.se
CENTRE FOR AGEING AND HEALTH
- AGECAP
EPINEP Neuropsychiatric
Epidemiology Department of Psychiatry and Neurochemistry
Institute of Neuroscience and Physiology
Sahlgrenska Academy
University of Gothenburg
Research Group Leader: Ingmar Skoog
www.epinep.gu.se
Seniora Forskare
Margda Waern
Svante Östling
Anna Zettergren
Silke Kern
Hanna Falk
Elisabet Rothenberg
Kerstin Frändin
Tore Hällström
Ingvar Karlsson
Deborah Gustafson
Disputerade forskare
Pia Gudmundsson
Xinxin Guo
Helena Hörder
Lena Johansson
Jürgen Kern
Madeleine Mellqvist Fässberg
Simona Sacuíu
Robert Sigström
Stefan Wiktorsson
Daniel Jaraj
Doktorander
Jenna Al-Najjar
Erik Joas
Isak Fredén Klenfeldt
Johan Nilsson
Mats Ribbe
Therese Rydberg
Johan Skoog
Felicia Nord
Hanna Wetterberg
Lina Rydén
Jessica Samuelsson
Vetenskaplig koordinator
Anna Zettergren
Administrativ koordinator
Tina Jacobsson
Statistiker
Valter Sundh
Erik Joas
Yadi Nejad
Nazib Seidu
![Page 4: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/4.jpg)
Gothenburg
![Page 5: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/5.jpg)
NEUROPSYCHIATRIC EPIDEMIOLOGY
THE GOTHENBURG H70 BIRTH COHORT STUDIES
Demented
(N) %
Men (N=75) 37
Women (N=263) 56 *
•H70-study
•H85-study
•The 95+ Study
•The Prospective Population Study of Women (PPSW)
•Representative samples based on birth dates
![Page 6: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/6.jpg)
H70
(Total N=6200)
Ålder 70 75 79 81 83 85 88 90 92 95 97 99 100 101
1901-02 + + + + + + + + + + + + + +
1906-07 + + +
1911-12 + +
1922 + + + +
1930 + + + + (+)
1944 + (+)(+) (+)
Systematic samples of 70-year-olds living in Gothenburg sampled from the Swedish
Population Register selected based on birth dates (e.g. 2, 5, 8, 12, 15, 18 etc)
![Page 7: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/7.jpg)
H85 GÖTEBORG
(Total N=1556)
Age 85 88 90 92 95 97 99
1901-02 + + + + + + +
1923-24 + + + +
1930 + (+) (+)
Systematic samples from the Swedish Population Register
selected based on birth dates (e.g. 2, 5, 8, 12, 15, 18 etc)
![Page 8: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/8.jpg)
Prospective Population Study of Women
in Gothenburg
Year of examination and ages studied
Cohort 1968 1974 1981 1992 2000 2005 2010 2016
1908 60 66 73 84 92 97 101 108
1914 54 60 67 78 86 91 95 102
1918 50 56 63 74 82 87 91 98
1922 46 52 59 70 78 83 87 94
1930 38 44 51 62 70 75 79 86
N 1462 661 580 450 250
![Page 9: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/9.jpg)
•Neuropsychiatric examination
•Key informant interview
•Medical examination (somatic disorders, alcohol, smoking)
•Functional ability (ADL, iADL)
•Anthropometry (length, weight etc)
•Social interview (social network, physical, social and cultural activities, life
events, working life etc)
•Psychometric testings
•Personality (Eysenck, Five Factor, KASAM)
•Focus groups
•Gender
•Blood, serum, plasma
•Genetic analyses
•ECG, blood pressure
•Lung function
•Physical function (walking speed, hand grip, balance, chair stand etc)
•Audiology
•Ophtalmology
•Dietary examination, DEXA (bone, muscle, fat)
•CT and MRI of brain
•Lumbar puncture/ Neurochemistry
General examinations
![Page 10: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/10.jpg)
MRI (N=850)
3 teslas MRI
Usual MR-sequences (T1, T2, FLAIR)
Newer techniques
Susceptibility weighted imaging
Diffusion tension imaging
Resting state fMRI (‘default mode network’)
![Page 11: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/11.jpg)
MRI CSF Cognitive function Psychiatric disorders Personality
Dexa (fat, muscle, bones) ECG Blood samples Genetic factors
External factors
![Page 12: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/12.jpg)
www.gu.se
Preclinical dementia
![Page 13: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/13.jpg)
Life-course epidemiology
0 100
= risk factor
= protective Preclinical
AD Dementia
![Page 14: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/14.jpg)
CLINICAL COURSE OF ALZHEIMERS DISEASE
Dementia
Memory
Language
ADL
Social ability
Spatial ability
Aggressivness
Apathy
Personality changes
![Page 15: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/15.jpg)
Cerebrospinal fluid markers in
Alzheimer’s disease
Low beta-amyloid-42
High total tau
High phospho-tau
![Page 16: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/16.jpg)
Jack et al. Lancet Neurology 2013
Temporal ordering of the pathological processes of AD
![Page 17: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/17.jpg)
CSF-abeta
CSF-tau
MRI atrophy
Memory
MCI
Dementia
PET amyloid
PET tau
0 20 Duration years
Preclinical AD
![Page 18: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/18.jpg)
Jack et al. Lancet Neurology 2013
Risk factors and
initiators
Accelerators
Deaccelerators
Time line of pathological processes in AD
![Page 19: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/19.jpg)
How common is preclinical AD?
![Page 20: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/20.jpg)
Preclinical dementia in CSF (Dubois criteria)
in a population sample of 70-year-olds
with CDR 0
%
Pathological beta-amyloid-42 23
Pathological total-tau 33
Pathological p-tau 7
Precliniscal Alzheimer
(amyloid AND tau pathology)
10
Any Alzheimerpathology 46
Kern, Skoog et al Neurology 2018
![Page 21: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/21.jpg)
Venn diagram of the ATN distribution of amyloid and tau pathology of 70-year-
olds with CDR 0.
CENTRE FOR AGEING AND HEALTH
- AGECAP
Kern et al. Neurology 2018
![Page 22: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/22.jpg)
Kern, Skoog et al Neurology 2018
ApoE e4 Low beta-amyloid 42
70-year-olds born 1944 with CDR 0
Male sex Higher total-tau
![Page 23: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/23.jpg)
Poor sleep Low CSF Beta-amyloid 42
Skoog J et al 2018
70-year-olds born 1944
Higher
CSF t-tau, p-tau, neurogranin
Lower CSF Beta-amyloid 42
Individuals with ApoE e4
Poor sleep
![Page 24: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/24.jpg)
When does AD start?
And when is it a disorder?
![Page 25: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/25.jpg)
The Prospective Population Study of
Women
Ages at examination
Year of examination and ages of participants
Cohort 1968 1974 1981 1992 2000 2005 2009
1908 60 66 73 84 92 97 101
1914 54 60 67 78 86 91 95
1918 50 56 63 74 82 87 91
1922 46 52 59 70 78 83 87
1930 38 44 51 62 70 75 79
N 1462 86
![Page 26: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/26.jpg)
CSF-biomarkers in 1992 in relation to
dementia during 18-year follow-up
No
dementia
Dementia onset
Year of follow-
up
0-18 years
(N=62)
0-8
years
(N=6)
9-13
years
(N=10)
14-18
years
(N=8)
Beta-amyloid
1-42
865.2 655.2* 648.0** 767.5*
Total tau 321.3 546.3* 311.5 235.3
Skoog, Kern, Blennow, Zetterberg 2018
![Page 27: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/27.jpg)
Red squares=Alzheimer's, Green=vascular dementia, circles=not dementia
0
200
400
600
800
1000
1200
1400
0 20 40 60 80 100 120 140
Am
ylo
id-β
42
Tau
Amyloid-β 42 and t-Tau from CSF 1992 and development of dementia until 2009
![Page 28: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/28.jpg)
Dementia Alzheimer’s disease
1992-2000 1992-2005 1992-2010 1992-2000 1992-2005 1992-2010
Sensitivity 83.3 83.3 73.1 100.0 100 94.1
Specificity 60.0 60.0 60.0 60.0 60.0 60.0
PPV 17.2 38.5 44.2 17.2 33.3 40.0
NPV 97.3 92.3 83.7 100.0 100.0 97.3
Skoog et al 2018
Sensitivity, specificity, PPV and NPV
for below median of beta-amyloid in
relation to dementia during 18 years
follow-up
Pathological beta-amyloid 5/12 became demented
![Page 29: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/29.jpg)
What happens very early in the
disease process?
![Page 30: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/30.jpg)
H85 GÖTEBORG
(Total N=1556)
Age 85 88 90 92 95 97 99
1901-02 + + + + + + +
1923-24 + + + +
1930 + (+) (+)
Systematic samples from the Swedish Population Register
selected based on birth dates (e.g. 2, 5, 8, 12, 15, 18 etc)
![Page 31: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/31.jpg)
THE SAHLGRENSKA ACADEMY
Concomitant pathology biomarkers • Total tau- a marker for neuronal damage
– A microtubule binding protein promoting stability
– Major increases in CSF from patients with CJD
– Increases after acute stroke
– 2-3-fold increased in AD
• Neurogranin- a marker for synaptic degeneration
– a postsynaptic protein involved in the regulation of synaptic signaling
through its binding to calmodulin at low levels of calcium
– CSF levels significantly increased in MCI and AD
- High CSF levels correlate with a more rapid change in cognition during
clinical follow-up (Kvartsberg et al 2014).
31 Höglund et al. Transl Psychiatry 2017
![Page 32: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/32.jpg)
THE SAHLGRENSKA ACADEMY
Concomitant pathology biomarkers
• P-Tau(181)- a marker for tangle pathology
– Phosphorylation of tau regulates binding to microtubule
– Hyperphosphorylation of tau seem to be specific to AD
– 2-3fold increases in CSF in AD
• YKL-40 (chitinase 3-like-1)- a marker for reactive astrocytes
– Increased in CSF in AD and FTD
– Increases in CSF may suggest future cognitive decline (Craig-Shapiro et
al 2011)
Höglund et al. Transl Psychiatry 2017
![Page 33: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/33.jpg)
THE SAHLGRENSKA ACADEMY
Healthy elderly with amyloid pathology also display signs of neuronal damage (total tau) and tangle pathology (p-tau)
Höglund et al. Transl Psychiatry 2017
total tau, p< 0.001 p-tau, p< 0.001
![Page 34: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/34.jpg)
THE SAHLGRENSKA ACADEMY
Healthy elderly with amyloid pathology also display signs of inflammation (YKL-40) and synaptic damage (neurogranin)
Höglund et al. Transl Psychiatry 2017
YKL-40, p< 0.044 Neurogranin, p< 0.011
![Page 35: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/35.jpg)
THE SAHLGRENSKA ACADEMY
Cognitively healthy elderly individuals with amyloid pathology display:
• neuronal damage (t-tau and neurogranin),
• tangle pathology (p-tau) and
• microglial activation (YKL-40).
Höglund et al. Transl Psychiatry 2017
![Page 36: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/36.jpg)
THE SAHLGRENSKA ACADEMY
WHAT ABOUT VASCULAR FACTORS IN PRECLINICAL AD?
![Page 37: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/37.jpg)
Ischemic white matter lesions a
silent disease of the brain
![Page 38: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/38.jpg)
Permission from Philip Scheltens
White matter lesions on MRI
![Page 39: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/39.jpg)
WHITE MATTER LESIONS ON CT
Demented
(N) %
Men (N=75) 37
Women (N=263) 56 *
![Page 40: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/40.jpg)
Permission from Arne Brun
![Page 41: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/41.jpg)
Permission from Arne Brun
![Page 42: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/42.jpg)
Prevalence of WMLs in normal
elderly
MRI: 50-100% depending on age and scale
CT: 55-70% depending on age and scale
![Page 43: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/43.jpg)
White matter lesions on CT and
the development of
dementia during a 10 year follow-up
OR (95%-CI)
Depression 3.8 (1.3-7.2)
Dementia 4.0 (1.2-11.8)
Gudmundsson et al. Eur J Neurol 2015
![Page 44: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/44.jpg)
The relation between CSF beta-amyloid-42 and
severity of WMLs and brain atrophy in individuals
with and without dementia
Individuals
Without dementia
(N=29)
With dementia
(N=22)
Interaction with
dementia
p
Frontal atrophy 0.12 -0.52* 0.02
Temporal atrophy -0.15 -0.70*** 0.03
Parietal atrophy -0.13 -0.59*** 0.11
WMLs -0.39** 0.03 0.10
Skoog, et al. J Alz Dis 2018
![Page 45: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/45.jpg)
DENSITY OF SENILE PLAQUES
IN PARAHIPPOCAMPAL GYRUS (number/mm2) IN
MIDDLE-AGED INDIVIDUALS
Controls 5
Hypertension 17*
Coronary artery 9*
CAD/Hypertension 14*
Alzheimer 34*
Sparks et al J Neurol Sci 1995; 131:162-169
![Page 46: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/46.jpg)
Thus, early interaction between
vascular factors and amyloid
![Page 47: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/47.jpg)
Jack et al. Lancet Neurology 2013
Temporal ordering of the pathological processes of AD
WMLs
Hypertension
?
?
![Page 48: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/48.jpg)
Life-time perspective
![Page 49: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/49.jpg)
Life-course epidemiology
0 100
= risk factor
= protective Preclinical
AD
![Page 50: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/50.jpg)
Severe psychological stress in middle-
aged women 1968-80 in relation to
development of dementia up to 2000
Severe
stress
OR (95%-CI)
1968 1.6 (1.1-2.3)
1974 1.6 (1.1-2.3)
1980 1.6 (1.0-2.6)
Stress
1968-80
2.4 (1.2-4.7)
Johansson et al Brain 2010
![Page 51: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/51.jpg)
Severe psychological stress 1968-80
in relation to WMLs in 2000 Severe
stress
OR (95%-CI)
1968 1.7 (0.8-3.6)
1974 1.2 (0.6-2.4)
1980 3.0 (1.4-6.2)
Stress
1968-80
2.2 (1.0-4.5)
Johansson et al Psychosomatic Med 2012
![Page 52: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/52.jpg)
Midlife psychosocial stress 1968-1980
Higher total-tau, VILIP-1, MBP in 1992
Johansson et al Dement Geriatr Cogn Disord. 2018;46(1-2):90-99
VILIP-1 = visinin-like protein 1
MBP= myelin basic protein
![Page 53: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/53.jpg)
Stress and negative events may lead to a life-
long increased level of cortisol
Increased cortisol may lead to damage in the
brain, especially in the hippocampus
Thus, when does the disease start?
![Page 54: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/54.jpg)
Life-time depression and risk of dementia over 44 years
Dem (N)/Depr (N) Dementia
HR 95%CI
Depression onset <20 year
Depression onset 20-49 year
Depression onset 50-69 year
Depression onset ≥70
12/33 (36%)
63/327 (19%)
8/58 (14%)
22/64 (34%)
3.35 (1.70-6.59)
1.66 (1.06-2.59)
0.97 (0.44-2.13)
2.16 (1.22-3.79)
Table (n=713, AD=133 (18%))
HR compared to persons with no depression (28/248,
11%); Adj to age, education, ApoE4 presence
Johansson, Skoog et al 2018
![Page 55: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/55.jpg)
Dementia
subtypes
Risk
variable
Years Incident
at risk cases HR (95% CI)
All dementia1
Intellectual
Physical
6792 109
0·75 (0·58–0·96)
0·61 (0·39–0·96)
Alzheimer’s
disease2
Artistic
6363 55
0·63 (0·42–0·93)
Vascular
dementia3
Club
Physical
5929 25
1·79 (1·04–3·10)
0·39 (0·16–0·96)
Mixed
dementia4
Intellectual
Physical
5883 19
0·24 (0·08–0·69)
0·32 (0·12–0·85)
Al-Najjar et al. 2018
Relationships between specific cognitive engagements and
physical activity in midlife 1968 and dementia in ages 70-84
years
![Page 56: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/56.jpg)
Working capacity at ergometer bicycle in 1968
in relation to dementia incidence 19868-2012
Working
capacity
Dementia
HR (95%-CI)
High 0.13 (0.03-0.56)
Medium 1.0
Low 3.1 (1.4-6.8)
Hörder et al Neurology 2018
![Page 57: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/57.jpg)
Jack et al. Lancet Neurology 2013
Time line of pathological processes in AD
Risk factors and
initiators
Accelerators
Deaccelerators
![Page 58: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/58.jpg)
Non-brain markers of preclinical
AD
![Page 59: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/59.jpg)
Blood pressure trajectories in relation to
late life dementia in women followed for 38 years
Joas et al. Hypertension 2012
![Page 60: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/60.jpg)
A 15-year follow-up of
blood pressure and Alzheimer’s disease
Demented
(N) %
Men (N=75) 37
Women (N=263) 56 *
Skoog et al. Lancet 1996
![Page 61: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/61.jpg)
Trajectories of BMI over 37 years in women
in relation to late-life dementia
Gustafson et al. J Alz Dis (2012)
![Page 62: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/62.jpg)
CSF-abeta
CSF-tau
MRI atrophy
Memory
MCI
Dementia
PET amyloid
PET tau
0 20 Duration years
Preclinical AD
ApoE e4, poor sleep
Psychosocial stress Vascular factors
Hypertension
WMLs Lower bloood pressure
![Page 63: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/63.jpg)
Life-course perspective Dynamic influences from birth to old age
Windows of oppurtunity for prevention?
Dementia can be prevented
We do not know enough on when, where and how the
effects takes place
Most epidemiological studies on risk factors are less
than 20 years
Most prevention studies are less than 5 years
We need to rely more on data from observational
studies for public prevention programs
RCTs are over-rated and should be used with care
![Page 64: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/64.jpg)
Possible preventive factors
• Treat vascular disorders and risk factors
• Fitness
• Physical activity
• Cognitive activity
• Decrease stress
• Treat neuroticism
• Sleep well
• Healthy diet
• Increase education
![Page 65: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/65.jpg)
Vascular risk factors for AD
ApoE e4 (1993)
Hypertension (1996)
Hypercholesterolemi (1997)
Diabetes mellitus (1997)
Atheroscleros (1997)
Overweight (2003)
![Page 66: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/66.jpg)
Sahlgrenska akademin
Neuropsychiatric Epidemiology
EPINEP
![Page 67: Preclinical dementia Implications for prevention · 2018. 12. 4. · Research Group Leader: Ingmar Skoog Xinxin Seniora Forskare Margda Waern Jenna Al Svante Östling Anna Zettergren](https://reader035.vdocuments.us/reader035/viewer/2022071413/610ac158db06ff0f1f09c310/html5/thumbnails/67.jpg)
http://iagger2019.se
See you in Gothenburg!